Yonghua Capital

Yonghua Capital is a prominent Chinese private equity firm specializing in healthcare and biotechnology investments. As a subsidiary of Yongjin Group, it has over 20 years of experience in private equity and fund management, focusing on high-quality companies with core competencies. The firm has invested in nearly 200 companies, with over 60 successfully listed on the A-share market, achieving excellent returns for its investors. The firm's investment strategy encompasses various stages, including seed, early stage, growth, late stage, pre-IPO, buyout, turnaround, and distressed investments. Yonghua Capital's geographical focus spans multiple countries, including China, the United States, the United Kingdom, Germany, Israel, Canada, France, Italy, Spain, Serbia, South Africa, Mexico, Brazil, Denmark, Romania, South Korea, Japan, India, Singapore, and Australia. Its industry focus includes high-tech equipment and advanced manufacturing, new energy and new materials, IT and communication technology, medical and healthcare, energy efficiency and environmental protection, culture and athletics, and consumer products. Yonghua Capital's investment philosophy emphasizes enhancing the value of Chinese enterprises by improving internal structures, streamlining financial management, recruiting elite talents, and optimizing resource integration. The firm has established close cooperation with securities companies, law firms, and accounting firms, ensuring comprehensive support from investment services to various investment banking services. This approach has enabled Yonghua Capital to identify undervalued companies and obtain returns from the capital market effectively.